Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biocryst Pharmaceuticals Inc (BCRX)  
$6.46 0.11 (1.67%) as of 4:30 Fri 5/31


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 189,490,000
Market Cap: 1.22(B)
Last Volume: 3,831,904 Avg Vol: 4,453,128
52 Week Range: $4.13 - $8.81
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    : 16.2
Insider 6 Months    : 16.2
Insider 3/6 Months : 31.2
Guru Rank Number :  455
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 175,740 175,740 175,740 175,740
Total Buy Value $998,342 $998,342 $998,342 $998,342
Total People Bought 9 9 9 9
Total Buy Transactions 9 9 9 9
Total Shares Sold 0 0 16,866 495,199
Total Sell Value $0 $0 $135,363 $5,999,241
Total People Sold 0 0 2 9
Total Sell Transactions 0 0 2 14
End Date 2024-03-03 2023-12-01 2023-06-02 2022-06-02

   
Records found: 475
  Page 18 of 19  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2015-03-19 4 S $10.16 $122,987 D/D (12,105) 148,697     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2015-03-05 4 S $10.59 $396,066 D/D (37,400) 160,802     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2015-03-04 4 S $10.50 $110,198 D/D (10,495) 198,202     -
   Sheridan William P Senior VP - CMO   •       •      –    2015-03-01 4 D $10.20 $17,738 D/D (1,739) 95,123     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2015-03-01 4 D $10.20 $16,667 D/D (1,634) 208,697     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2015-03-01 4 D $10.20 $4,743 D/D (465) 165,144     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2015-03-01 4 D $10.20 $11,424 D/D (1,120) 71,876     -
   Stonehouse Jon P President & CEO   •       •      –    2015-03-01 4 D $10.20 $52,204 D/D (5,118) 650,869     -
   Cohen Fred E Director   •       •      –    2015-02-27 4 A $10.20 $8,741 D/D 857 102,314     -
   Hutson Nancy J Director   •       •      –    2015-02-20 4 B $10.27 $102,700 D/D 10,000 15,891 2.39     -
   Powell Lynne Senior VP - CCO   •       •      –    2015-01-26 4 A $0.00 $0 D/D 10,000 10,000     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2015-01-20 4 D $11.17 $24,686 D/D (2,210) 72,370     -
   Sheridan William P Senior VP - CMO   •       •      –    2015-01-20 4 D $11.17 $56,677 D/D (5,074) 95,609     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2015-01-20 4 D $11.17 $48,724 D/D (4,362) 210,331     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2015-01-20 4 D $11.17 $49,997 D/D (4,476) 164,913     -
   Stonehouse Jon P President & CEO   •       •      –    2015-01-20 4 D $11.17 $118,491 D/D (10,608) 654,280     -
   Cohen Fred E Director   •       •      –    2015-01-08 4 OE $1.29 $129,000 D/D 100,000 101,457     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2015-01-01 4 D $12.16 $29,208 D/D (2,402) 214,693     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2015-01-01 4 A $0.00 $0 D/D 8,900 217,095     -
   Sheridan William P Senior VP - CMO   •       •      –    2015-01-01 4 D $12.16 $33,258 D/D (2,735) 100,683     -
   Sheridan William P Senior VP - CMO   •       •      –    2015-01-01 4 A $0.00 $0 D/D 10,900 103,418     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2015-01-01 4 D $12.16 $29,828 D/D (2,453) 169,389     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2015-01-01 4 A $0.00 $0 D/D 8,900 171,842     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2015-01-01 4 D $12.16 $29,828 D/D (2,453) 74,580     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2015-01-01 4 A $0.00 $0 D/D 4,800 77,033     -
  475 Records found
  Previous  10  11  12  13  14  15  16  17  18  19   
  Page 18 of 19
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us